THE THERAPEUTIC VALUE OF POLY(ETHYLENE GLYCOL)-MODIFIED PROTEINS

被引:248
作者
NUCCI, ML [1 ]
SHORR, R [1 ]
ABUCHOWSKI, A [1 ]
机构
[1] ENZON INC,S PLAINFIELD,NJ 07080
关键词
ENZYME; ENZYME REPLACEMENT; ENZYME THERAPY; MONOMETHOXYPOLY(ETHYLENE GLYCOL); MONOMETHOXYPOLY(ETHYLENE GLYCOL)-MODIFIED; PEGNOLOGY; PROTEIN MODIFICATION; PROTEIN THERAPY;
D O I
10.1016/0169-409X(91)90037-D
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The field of protein therapy has flourished in the past few years, mainly due to the advent of recombinant DNA techniques and large-scale manufacturing processes. It was believed that human-derived proteins would eliminate the problems of short circulating lives, low stability and immunogenicity associated with the use of non-human proteins as drugs. Unfortunately, it has been demonstrated that many human proteins still suffer from short circulating lives and low stability, and often require the use of large doses to maintain therapeutic efficacy. This in turn increases the chances for the development of an adverse immune response, or at least for the development of clearing antibodies. The discovery that the modification of proteins with poly(ethylene glycol) (PEGNOLOGY(SM)) results in an adduct with decreased to non-existent immunogenicity increased circulating life, increased stability and opened the way for the development of protein pharmaceuticals that would realize the promise of protein therapy. In this paper, we will review the clinical value of PEGNOLOGY(SM) as researched by Enzon Inc. and discuss the future for this technology.
引用
收藏
页码:133 / 151
页数:19
相关论文
共 140 条
  • [91] DEVELOPMENT OF A PERFLUOROCHEMICAL EMULSION AS A BLOOD-GAS CARRIER
    MITSUNO, T
    OHYANAGI, H
    YOKOYAMA, K
    [J]. ARTIFICIAL ORGANS, 1984, 8 (01) : 25 - 33
  • [92] MOSS GS, 1984, SURGERY, V95, P249
  • [93] MOSSMAN B T, 1986, Journal of Free Radicals in Biology and Medicine, V2, P335, DOI 10.1016/S0748-5514(86)80033-2
  • [94] INHIBITION OF LUNG INJURY, INFLAMMATION, AND INTERSTITIAL PULMONARY FIBROSIS BY POLYETHYLENE GLYCOL-CONJUGATED CATALASE IN A RAPID INHALATION MODEL OF ASBESTOSIS
    MOSSMAN, BT
    MARSH, JP
    SESKO, A
    HILL, S
    SHATOS, MA
    DOHERTY, J
    PETRUSKA, J
    ADLER, KB
    HEMENWAY, D
    MICKEY, R
    VACEK, P
    KAGAN, E
    [J]. AMERICAN REVIEW OF RESPIRATORY DISEASE, 1990, 141 (05): : 1266 - 1271
  • [95] MUELLER U, 1985, INT ARCH ALLER A IMM, V68, P320
  • [96] MUSS HB, 1990, INVEST NEW DRUG, V8, P125
  • [97] NHO K, IN PRESS BOVINE HEMO
  • [98] NISHI K, 1987, BIOMATER ARTIF CELL, V15, P381
  • [99] IMPROVED MODIFICATION OF YEAST URICASE WITH POLYETHYLENE-GLYCOL, ACCOMPANIED WITH NON-IMMUNOREACTIVITY TOWARDS ANTI-URICASE SERUM AND HIGH ENZYMIC ACTIVITY
    NISHIMURA, H
    MATSUSHIMA, A
    INADA, Y
    [J]. ENZYME, 1981, 26 (01) : 49 - 53
  • [100] MODIFICATION OF BATROXOBIN WITH ACTIVATED POLYETHYLENE-GLYCOL - REDUCTION OF BINDING ABILITY TOWARDS ANTI-BATROXOBIN ANTIBODY AND RETENTION OF DEFIBRINOGENATION ACTIVITY IN CIRCULATION OF PREIMMUNIZED DOGS
    NISHIMURA, H
    TAKAHASHI, K
    SAKURAI, K
    FUJINUMA, K
    IMAMURA, Y
    OOBA, M
    INADA, Y
    [J]. LIFE SCIENCES, 1983, 33 (15) : 1467 - 1473